[SAN DIEGO, USA – May 14^th, 2025] – The animal stem cell therapy market will grow at 26% CAGR to USD 3.8B by 2031, per a new 340-page ClearView report. Key developments:

Request Sample @ https://clearviewmarketinsights.com/report-details/animal-stem-cell-therapy-market/

Industry Shifts

1. Clinical Breakthroughs:
• VetStem’s Canine OA Treatment: 85% of dogs resume play within 8 weeks.
• Magellan’s Equine Amniotic Therapy boasts a 90% return-to-track rate for racehorses.
2. Regulatory Momentum:
• FDA’s 2026 approval of first allogeneic stem cell bank for dogs.
• EU bans corticosteroid injections for equine sports injuries (2027).
3. Consumer Demand:
• 72% of pet owners choose stem cells over joint surgery (AVMA survey).
• "Stem Cell-Certified" breeding dogs sell at 40% premium.

Executive Quotes

• Dr. Robert Harman, VetStem CEO:
  "We’re making hip replacements obsolete for dogs."
• Dr. Steven St. Peter, Aratana CEO:
  "Our off-the-shelf cells cut treatment costs and wait times in half."

Future Projections

• 2027: First stem cell therapy for feline diabetes.
• 2030: 25% of veterinary clinics offer in-house cell processing.

For more insights, visit https://clearviewmarketinsights.com/

About ClearView Market Insights Analytics

ClearView Market Insights Analytics is a global leader in industrial technology research, offering actionable insights across more than 100 laser market segments.

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369